Recent Updates
Recently added Catalysts

ABT-072

Phase 2

Hepatitis C Virus Infection | Small molecule | Infectious Disease |AbbVie Inc.|Last Updated: Apr 1, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment5
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00872196A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 StudiesPHASE2 COMPLETED 5Apr 1, 2009Apr 1, 2010Apr 1, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Analysis of the prevalence of resistance of specific mutations over time will be summarized.
Approximately 48 weeks.
Analysis of the degree of phenotypic resistance (fold change in susceptibility of ABT-072 compared to wild-type virus) will also be summarized.
Approximately 48 weeks.
Secondary Endpoints
Summary of serious adverse events related to study procedures only.
Approximately 48 weeks.
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
Treatment Arms
ArmTypeDescription
1 - Follow-up StudyOTHERThis is a follow-up study with no treatment and only samples being collected.
Interventions
NameTypeDescription
ABT-072DRUGBlood samples are being taken from subjects previously treated with ABT-072.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: \- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072. Exclusion Criteria: \- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with...

Countries:United States
Unlock Eligibility Criteria